Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Chapla Agarwal and Michael Wempe.

 
Connection Strength
 
 
 
1.094
 
  1. Tyagi A, Kumar S, Raina K, Wempe MF, Maroni PD, Agarwal R, Agarwal C. Differential effect of grape seed extract and its active constituent procyanidin B2 3,3?-di-O-gallate against prostate cancer stem cells. Mol Carcinog. 2019 07; 58(7):1105-1117.
    View in: PubMed
    Score: 0.208
  2. Kumar R, Deep G, Wempe MF, Surek J, Kumar A, Agarwal R, Agarwal C. Procyanidin B2 3,3?-di-O-gallate induces oxidative stress-mediated cell death in prostate cancer cells via inhibiting MAP kinase phosphatase activity and activating ERK1/2 and AMPK. Mol Carcinog. 2018 Jan; 57(1):57-69.
    View in: PubMed
    Score: 0.188
  3. Kumar R, Deep G, Wempe MF, Agarwal R, Agarwal C. Procyanidin B2 3,3?-di-O-gallate inhibits endothelial cells growth and motility by targeting VEGFR2 and integrin signaling pathways. Curr Cancer Drug Targets. 2015; 15(1):14-26.
    View in: PubMed
    Score: 0.156
  4. Tyagi A, Raina K, Shrestha SP, Miller B, Thompson JA, Wempe MF, Agarwal R, Agarwal C. Procyanidin B2 3,3(?)-di-O-gallate, a biologically active constituent of grape seed extract, induces apoptosis in human prostate cancer cells via targeting NF-?B, Stat3, and AP1 transcription factors. Nutr Cancer. 2014; 66(4):736-46.
    View in: PubMed
    Score: 0.144
  5. Shrestha SP, Thompson JA, Wempe MF, Gu M, Agarwal R, Agarwal C. Glucuronidation and methylation of procyanidin dimers b2 and 3,3?-di-o-galloyl-b2 and corresponding monomers epicatechin and 3-o-galloyl-epicatechin in mouse liver. Pharm Res. 2012 Mar; 29(3):856-65.
    View in: PubMed
    Score: 0.125
  6. Dhar D, Raina K, Kumar D, Wempe MF, Bagby SM, Pitts TM, Orlicky DJ, Agarwal C, Messersmith WA, Agarwal R. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. Mol Carcinog. 2020 10; 59(10):1227-1240.
    View in: PubMed
    Score: 0.058
  7. Dhar D, Raina K, Kant R, Wempe MF, Serkova NJ, Agarwal C, Agarwal R. Bitter melon juice-intake modulates glucose metabolism and lactate efflux in tumors in its efficacy against pancreatic cancer. Carcinogenesis. 2019 Sep 18; 40(9):1164-1176.
    View in: PubMed
    Score: 0.054
  8. Dhar D, Deep G, Kumar S, Wempe MF, Raina K, Agarwal C, Agarwal R. Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog. 2018 09; 57(9):1166-1180.
    View in: PubMed
    Score: 0.049
  9. Tilley C, Deep G, Agarwal C, Wempe MF, Biedermann D, Valentov√° K, Kren V, Agarwal R. Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation. Mol Carcinog. 2016 Jan; 55(1):3-14.
    View in: PubMed
    Score: 0.039
  10. Kavitha CV, Jain AK, Agarwal C, Pierce A, Keating A, Huber KM, Serkova NJ, Wempe MF, Agarwal R, Deep G. Asiatic acid induces endoplasmic reticulum stress and apoptotic death in glioblastoma multiforme cells both in vitro and in vivo. Mol Carcinog. 2015 Nov; 54(11):1417-29.
    View in: PubMed
    Score: 0.038
  11. Kaur M, Deep G, Jain AK, Raina K, Agarwal C, Wempe MF, Agarwal R. Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells. Carcinogenesis. 2013 Jul; 34(7):1585-92.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)